The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. CAPITAL AT RISK.

SpectrumX are currently raising £10m pre-IPO

Check your email for an investor pack with further information. We have passed your details to SpectrumX’s Investor Relations Team. They will reach out shortly to introduce themselves. If you’d prefer to pick a time that suits you, click below.

Book a Call With Investor Relations
FURTHER INFORMATION

What is Hypochlorous Acid?

SpectrumX are leaders in proprietary formulations of HOCL (Hypochlorous Acid). Through their partnership with Spectrum Antimicrobials, California, USA they hold various licenses for the use of their unique formulations.

First discovered in 1834, it has taken the technological advancements of SpectrumX to, for the first time, produce a stable, efficacious formulation that performs in real world conditions.

“HOCL has been well researched, published and later cleared by FDA in different therapeutic areas including reduction of topical inflammation and topical pain as well as disinfection of food and food preparation areas. However, none of the above mentioned products have been able to provide stability at lower concentrations for safe use of the product on people. Spectrum Antimicrobials unique and patented formulations provide rapid disinfection in the presence of soil and other organic matter, at concentrations of 0.032% where other HOCL based products have been shown to certainly fail in stability and performance.”

Dr. Jerry Stonemetz
Medical Director, Johns Hopkins University Hospital

What Should I Do Next?

We have passed your details to their Investor Relations team. Please expect contact from them and check your email for an introductory email.

Visit Their Website

Visit Website
UPDATE

This Raise Has Proved Popular With Our Investors

This raise has proved very popular with initial investors and is filled faster than anticipated. Make sure you don’t miss out on this future biotech giant.

We have passed your details to their Investor Relations team. Please expect contact from them and check your email for an introductory email.

£1000000

Raised So Far

5000000

Formula Submitted To Antivirals Taskforce

$11.2bn

HOCL Market Value By 2026

Not sure where to start?

We’d recommend speaking to one of our consultants. To qualify,
you must be a high net worth individual or a sophisticated investor.
Quickly confirm your eligible and we’ll set things up.

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

The website should not be construed as advice, or a personal recommendation by IPOFactory. IPOFactory is not authorised and regulated by the Financial Conduct Authority (FCA). The content of this promotion is not authorised under the Financial Services and Markets Act 2000 (FSMA). Reliance on the promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the investment. UK residents wishing to participate in this promotion must fall into the category of sophisticated investor or high net worth individual as outlined by the Financial Conduct Authority (FCA).